Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial

Area of Science:

• Cardiology
• Endocrinology
• Exercise Physiology

Background:

• Chronic heart failure (CHF) involves neurohormonal imbalance, inflammation, and muscle wasting.
• Androgens, like testosterone, play roles in muscle function, strength, and possess anti-inflammatory and vasodilatory effects.

Purpose of the Study:

• To investigate the efficacy of testosterone replacement therapy (TRT) in improving functional capacity and symptoms in men with CHF.
• To assess the impact of TRT on skeletal muscle mass, strength, and inflammatory markers in heart failure patients.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 76 men with CHF.
• Participants received physiological doses of testosterone (5 mg Androderm) or placebo for up to 12 months.
• Primary endpoint was functional capacity assessed by the incremental shuttle walk test (ISWT).

Main Results:

• Testosterone therapy significantly improved exercise capacity (15% increase from baseline, P=0.006) compared to placebo.
• A greater proportion of men on TRT experienced symptom improvement (35% vs. 8%, P=0.01).
• No significant changes were observed in handgrip strength, muscle bulk, or TNF levels.

Conclusions:

• Testosterone replacement therapy is effective in enhancing functional capacity in men with moderately severe heart failure.
• TRT also leads to significant improvements in heart failure symptoms.